Cancer can be caused
solely1 by protein imbalances within cells, a study of ovarian cancer has found. The discovery is a major breakthrough because, until now,
genetic2 aberrations3 have been seen as the main cause of almost all cancer.
The research, published today in the journal Oncogene, demonstrates that protein imbalance is a powerful prognostic tool, indicating whether or not patients are likely to respond to chemotherapy and whether a
tumour4 is likely to spread to other sites.
The findings also open the possibility of new therapies aimed at measuring and preventing dangerous imbalances in cells.
Lead author Professor John Ladbury, Dean of the University of Leeds'
Faculty5 of Biological Sciences and Professor of Mechanistic Biology, said: "There has been huge investment in sequencing the human genome with the idea that if we get all the relevant genetic information we can predict whether you have a predisposition to cancer and, ultimately, use a precision medicine-based approach to develop a
therapeutic6 approach. Our study demonstrates that genetic screening alone is not enough."
The research, led by scientists at the University of Leeds and The University of Texas MD Anderson Cancer Center, focused on the "Akt pathway," a signalling pathway within cells that drives cancer formation and the spread of cancers through the body.
Under normal conditions, the cell receives external signals through a cell wall-bound receptor (FGFR2 in this study). As a result of this
stimulus7 the receptor is 'switched on' inside the cell. This results in the recruitment of signalling proteins and the
initiation8 of the Akt pathway, which is responsible for committing the cell to
proliferate9. In some cancerous cells, this pathway is
permanently10 switched on. A conventional approach to diagnosing this cancer would be to look for genetic
modification11 of the receptor (or recruited proteins), which could be responsible for maintaining the switched on state.
The new study looked at
isolated12 cancer cells without external
stimulation13 and found that the "Akt pathway" could be
activated14 without genetic
modifications15. Two proteins; Plcγ1 (pronounced "plc-gamma-1") and Grb2 (pronounced "grab-2"), compete for
binding16 to FGFR2. The relative concentration of these proteins will
dictate17 which one
binds18. When Plcγ1 prevails, it triggers the Akt pathway. In this way, an imbalance in the amount of the two proteins can lead to cell proliferation and cancer formation.